The fate of iron nanoparticles used for treatment of iron deficiency in blood using mass-spectrometry based strategies

Microchimica Acta

Volumn 184, Issue 10, 2017, Pages 3673-3680

  García Fernández, Jenifer ^a,c   Bettmer, Jörg ^a   Jakubowski, Norbert ^b   Panne, Ulrich ^b,c   Añón, Elena ^d   Montes Bayón, María ^a   Sanz Medel, Alfredo ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b BAM FEDERAL INSTITUTE FOR MATERIALS RESEARCH AND TESTING   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Bioavailability; HPLC; ICP MS; Iron sucrose nanoparticles; Serum; Speciation

Indexed keywords

EID: 85021846921     PISSN: 00263672     EISSN: 14365073     Source Type: Journal    
DOI: 10.1007/s00604-017-2388-8     Document Type: Article

References (33)

1. Auerbach M, Ballard H (2010) Clinical use of intravenous iron: administration, efficacy, and safety. Hematology 2010:338–347. doi:10.1182/asheducation-2010.1.338
2. Danielson BG (2004) Structure, chemistry and pharmacokinetics of intravenous iron agents. J. Am Soc Nephrol 15:S93–S98. doi:10.1097/01.ASN.0000143814.49713.C5
3. Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Pavía J, Cuenca J, García-Erce JA (2012) Perioperative intravenous iron; an upfront therapy for treating anaemia and reducing transfusion requirements. Nutr Hosp 27:1817–1836. doi:10.3305/nh.2012.27.6.6087
4. Sharp P, Srai SK (2007) Molecular mechanisms involved in intestinal iron absorption. World J Gastroenterol 13:4716–4724. doi:10.3748/wjg.v13.i35.4716
5. Hamstra RD, Block MH, Schocket AL (1980) Intravenous iron dextran in clinical medicine. JAMA 243:1726–1731. doi:10.1001/jama.243.17.1726
6. Marchasin S, Wallerstein R (1964) The treatment of iron-deficiency anemia with intravenous iron dextran. Blood 23:354–358
7. Jahn MR, Andreasen HB, Fütterer S, Nawroth T, Schünemann V, Kolb U, Hofmeister W, Muñoz M, Bock K, Meldal M, Langguth P (2011) A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer ®), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 78:480–491. doi:10.1016/j.ejpb.2011.03.016
8. Santosh S, Podaralla P, Miller B (2010) Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol. NDT Plus 3:341–342. doi:10.1093/ndtplus/sfq084
9. Cançado RD, Muñoz M (2011) Intravenous iron therapy: how far have we come? Rev Bras Hematol Hemoter 33:461–469. doi:10.5581/1516-8484.20110123
10. Zazo H, Colino CI, Lanao JM (2016) Current applications of nanoparticles in infectious diseases. J Control Release 224:86–102. doi:10.1016/j.jconrel.2016.01.008
11. Benítez-Martínez S, López-Lorente ÁI, Valcárcel M (2016) Determination of TiO2 nanoparticles in sunscreen using N-doped graphene quantum dots as a fluorescent probe. Microchim Acta 183:781–789. doi:10.1007/s00604-015-1696-0
12. Ruiz-Palomero C, Soriano ML, Valcárcel M (2017) Detection of nanocellulose in commercial products and its size characterization using asymmetric flow field-flow fractionation. Microchim Acta 184:1069–1076. doi:10.1007/s00604-017-2106-6
13. Gupta AK, Gupta M (2005) Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26:3995–4021. doi:10.1016/j.biomaterials.2004.10.012
14. Fütterer S, Andrusenko I, Kolb U, Hofmeister W, Langguth P (2013) Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J Pharm Biomed Anal 86:151–160. doi:10.1016/j.jpba.2013.08.005
15. Geisser P, Burckhardt S (2011) The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 3:12–33. doi:10.3390/pharmaceutics3010012
16. Wienk KJH, Marx JJM, Beynen AC (1999) The concept of iron bioavailability and its assessment. Eur J Nutr 38:51–75. doi:10.1007/s003940050046
17. Van Wyck D, Anderson J, Johnson K (2004) Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant 19:561–565. doi:10.1093/ndt/gfh370
18. Jomova K, Valko M (2011) Advances in metal-induced oxidative stress and human disease. Toxicology 283:65–87. doi:10.1016/j.tox.2011.03.001
19. Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product (2015) European Medicines Agency EMA/CHMP/SWP/620008/2012
20. Hu QH (2011) Simultaneous separation and quantification of iron and transition species using LC-ICP-MS. Am J Anal Chem 2:675–682. doi:10.4236/ajac.2011.26077
21. Faria N, Winship PD, Weiss DJ, Coles BJ, Schoenberg R, Hutchinson C, Pereira DIA, Powell JJ (2011) Development of DRC-ICP-MS methodology for the rapid determination of 58Fe erythrocyte incorporation in human iron absorption studies. J Anal At Spectrom 26:1648–1652. doi:10.1039/C1JA10103J
22. Fiorito V, Crich SG, Silengo L, Altruda F, Aime S, Tolosano E (2012) Assessment of iron absorption in mice by ICP-MS measurements of 57Fe levels. Eur J Nutr 51:783–789. doi:10.1007/s00394-011-0256-6
23. Del Castillo-Busto ME, Montes-Bayón M, Bettmer J, Sanz-Medel A (2008) Stable isotope labelling and FPLC–ICP-SFMS for the accurate determination of clinical iron status parameters in human serum. Analyst 133:379–384. doi:10.1039/b715311b
24. Nuevo Ordoñez Y, Montes-Bayón M, Blanco-González E, Paz-Jiménez J, Tejerina-Lobo JM, Peña-López JM, Sanz-Medel A (2009) Metal release in patients with total hip arthroplasty by DF-ICP-MS and their association to serum proteins. J Anal At Spectrom 24:1037–1043. doi:10.1039/B820339C
25. Del Castillo Busto ME, Montes-Bayón M, Garcia-Alonso JI, Caruso JA, Sanz-Medel A (2010) Novel HPLC-ICP-MS strategy for the determination of B-transferrin, the biomarker of cerebrospinal fluid leakage. Analyst 135:1538–1540. doi:10.1039/C0AN00207K
26. http://www.venofer.com. Accessed 14 Feb 2017
27. Danielson BG, Salmonson T, Derendorf H, Geisser P (1996) Pharmacokinetics of iron(III)- hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Drug Res 46:615–621
28. Sariego-Muñiz C, Fernández-Martin JL, Marchante Gayón JM, García Alonso JI, Cannata Andía JB, Sanz-Medel A (2001) Reference values for trace and ultratrace elements in human serum determined by double-focusing ICP-MS. Biol Trace Elem Res 82:259–272. doi:10.1385/BTER:82:1-3:259
29. Nuevo Ordoñez Y, Montes-Bayón M, Blanco-González E, Sanz-Medel A (2011) Titanium preferential binding sites in human serum transferrin at physiological concentrations. Metallomics 3:1297–1303. doi:10.1039/c1mt00109d
30. Anraku M, Kitamura K, Shinohara A, Adachi M, Suenaga A, Maruyama T, Miyanaka K, Miyoshi T, Shiraishi N, Nonoguchi H, Otagiri M, Tomita M (2004) Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int 66:841–848. doi:10.1111/j.1523-1755.2004.00813.x
31. Hahn A, Fuhlrott J, Loos A, Barcikowski S (2012) Cytotoxicity and ion release of alloy nanoparticles. J Nanopart Res 14:686–696. doi:10.1007/s11051-011-0686-3
32. Loza K, Diendorf J, Sengstock C, Ruiz-Gonzalez L, Gonzalez-Calbet JM, Vallet-Regi M, Köller M, Epple M (2014) The dissolution and biological effects of silver nanoparticles in biological media. J Mater Chem B 2:1634–1643. doi:10.1039/C3TB21569E
33. Écija-Arenas Á, Román-Pizarro V, Fernández-Romero JM, Gómez-Hens A (2016) Separation and purification of hydrophobic magnetite-gold hybrid nanoparticles by multiphase density gradient centrifugation. Microchim Acta 183:2005–2012. doi:10.1007/s00604-016-1838-z